NasdaqCM - Nasdaq Real Time Price USD

InspireMD, Inc. (NSPR)

2.3750

-0.0550

(-2.26%)

As of 3:52:38 PM EDT. Market Open.

InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges

Despite a rise in revenue and strategic advancements, InspireMD Inc (NSPR) faces increased expenses and a significant net loss.

GuruFocus.com 4 days ago

NSPR
-2.26%
InspireMD Reports First Quarter 2025 Financial Results

Management to host investor conference call today, May 9th, at 8:30am ETMIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the

GlobeNewswire 5 days ago

NSPR
-2.26%
InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time / 10:15AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company’s website at:

GlobeNewswire 14 days ago

NSPR
-2.26%
InspireMD to Announce First Quarter 2025 Financial Results

MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access t

GlobeNewswire 19 days ago

NSPR
-2.26%
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to 11 new non-executive employees in the aggregate amount of 299,398 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of April 1, 2025, as an inducement mat

GlobeNewswire last month

NSPR
-2.26%
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company’s webs

GlobeNewswire last month

NSPR
-2.26%
InspireMD Full Year 2024 Earnings: US$0.76 loss per share (vs US$0.82 loss in FY 2023)

InspireMD ( NASDAQ:NSPR ) Full Year 2024 Results Key Financial Results Revenue: US$7.01m (up 13% from FY 2023). Net...

Simply Wall St. 2 months ago

NSPR
-2.26%
InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ...

InspireMD Inc (NSPR) reports a 10.6% revenue increase in Q4 2024, while preparing for the anticipated US launch of CGuard Prime in 2025.

GuruFocus.com 2 months ago

NSPR
-2.26%
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Management to host investor conference call today, March 12th, at 8:30am ETMIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) ap

GlobeNewswire 2 months ago

NSPR
-2.26%
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested

GlobeNewswire 2 months ago

NSPR
-2.26%
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 78% over the last five years

InspireMD, Inc. ( NASDAQ:NSPR ) shareholders should be happy to see the share price up 13% in the last month. But spare...

Simply Wall St. 2 months ago

NSPR
-2.26%
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II pivotal study of Inspir

GlobeNewswire 2 months ago

NSPR
-2.26%
Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 3 months ago

NSPR
-2.26%
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025

MIAMI, Dec. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition. Marvin Slosman, Chief Executive Officer of InspireMD, commented, “Craig

GlobeNewswire 4 months ago

NSPR
-2.26%
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Study represents a significant step forward in Company’s mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutionsMIAMI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergo

GlobeNewswire 5 months ago

NSPR
-2.26%
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, sta

GlobeNewswire 5 months ago

NSPR
-2.26%

ABT
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)

InspireMD ( NASDAQ:NSPR ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.81m (up 16% from 3Q 2023). Net...

Simply Wall St. 5 months ago

NSPR
-2.26%
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...

InspireMD Inc (NSPR) reports a 16.3% revenue increase while navigating higher expenses and gearing up for a pivotal U.S. market entry.

GuruFocus.com 5 months ago

NSPR
-2.26%
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

– Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S. – – Announced approval of an IDE application to initiate the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures – – Established its Headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in H1 2025, if approved – Achieved another record high revenue and un

GlobeNewswire 5 months ago

NSPR
-2.26%
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2024 financial results on Tuesday, November 12th, 2024, before the financial markets open. Management will host a conference call and webcast with the investment comm

GlobeNewswire 6 months ago

NSPR
-2.26%

Performance Overview

Return	NSPR	S&P 500 (^GSPC)
YTD	-9.70%	+0.16%
1-Year	-0.21%	+12.28%
3-Year	+14.18%	+46.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InspireMD, Inc. (NSPR)

InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges

InspireMD Reports First Quarter 2025 Financial Results

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

InspireMD to Announce First Quarter 2025 Financial Results

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

InspireMD Full Year 2024 Earnings: US$0.76 loss per share (vs US$0.82 loss in FY 2023)

InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ...

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 78% over the last five years

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation

InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)

InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...

InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

Performance Overview